RT Journal Article
T1 Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
A1 Oliver, Javier
A1 Onieva Zafra, Juan Luis
A1 Garrido-Barros, María
A1 Berciano-Guerrero, Miguel Ángel
A1 Sánchez-Muñoz, Alfonso
A1 Lozano, María José
A1 Farngren, Angela
A1 Álvarez-Pérez, Martina
A1 Martínez-Gálvez, Beatriz
A1 Pérez-Ruiz, Elisabeth
A1 Alba-Conejo, Emilio
A1 Cobo Dols, Manuel Ángel
A1 Rueda-Domínguez, Antonio
A1 Barragán, Isabel
K1 Piel - Cáncer
K1 Cáncer - Inmunoterapia
K1 Melanoma
AB Cutaneous melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint inhibitors programmed death cell protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) constituted a main breakthrough in the treatment of metastatic CM, particularly for the achievement of long-term benefits. Even though it is a very promising therapy, resistance to primary immune checkpoint blockade (ICB) arises in about 70% of CM patients treated with a CTLA-4 inhibitor, and 40-65% of CM patients administered with a PD-1-targeting treatment. Some long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) are implicated in triggering pro- and anti-tumorigenic responses to various cancer treatments. The relationship between lncRNAs, circRNAs and ICB immunotherapy has not been explored in cutaneous metastatic melanoma (CMM). The aim of this pilot study is to evaluate the potential role of circRNA and lncRNA expression variability as pre-treatment predictor of the clinical response to immunotherapy in CMM patients. RNA-seq from 12 formalin-fixed paraffin-embedded (FFPE) samples from the metastatic biopsies of CMM patients treated with nivolumab was used to identify response-associated transcripts. Our findings indicate that specific lncRNAs and circRNAs, probably acting as competitive endogenous RNAs (ceRNAs), are involved in the regulatory networks of the immune response against metastatic melanoma that these patients have under treatment with nivolumab. Moreover, we established a risk score that yields predictions of the overall survival (OS) and progression-free survival (PFS) of CMM patients with high accuracy. This proof-of-principle work provides a possible insight into the function of ceRNAs, contributing to efforts to decipher the complex molecular mechanisms of ICB cancer treatment response.
PB MDPI
YR 2022
FD 2022
LK https://hdl.handle.net/10630/31232
UL https://hdl.handle.net/10630/31232
LA spa
NO Oliver J, Onieva JL, Garrido-Barros M, Berciano-Guerrero MÁ, Sánchez-Muñoz A, José Lozano M, Farngren A, Álvarez M, Martínez-Gálvez B, Pérez-Ruiz E, Alba E, Cobo M, Rueda-Domínguez A, Barragán I. Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma. Biomedicines. 2022 Sep 27;10(10):2419. doi: 10.3390/biomedicines10102419. PMID: 36289681; PMCID: PMC9599084.
NO Este artículo ha sido publicado en la revista Biomedicines. Esta versión tiene Licencia Creative Commons CC-BY
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026